New Cypriot system must address 'black spot' of access to meds, group says

2 July 2018

The creation of a National Health Scheme (NHS) for Cyprus must eradicate inequalities that exist today between the private and public sector, says Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA).

This group represents the innovative pharmaceutical industry in Cyprus and is having its say as the Cypriot government decides how to proceed with the NHS and issues including ensuring patients’ access to medicines.

The KEFEA described this as a “black spot” in the healthcare available in Cyprus today, saying that patients do not have access to all the treatments and even when this is possible, there are so many restrictions that it eventually becomes extremely difficult.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK